What question did this study set out to answer?

To evaluate the efficacy of therapeutic plasma exchange in managing transfusion-dependent pure red cell aplasia following ABO-incompatible hematopoietic stem cell transplantation.

January 26, 2023Journal of Clinical Apheresis

Successful treatment of pure red cell aplasia using therapeutic plasma exchange after ABO‐incompatible hematopoietic stem cell transplant

View Full Paper

Ask AI

Bookmark

Authors

AVAngelica ViveroThomas Jefferson University Hospital APAlexis R. PeedinLaboratoire de Conception et d'Intégration des Systèmes YGYuanzheng GaoCooper University Health Care

Discussion

Member takes

Implication

Case series demonstrates resolution of pure red cell aplasia using therapeutic plasma exchange after ABO-incompatible stem cell transplant, highlighting its utility in refractory cases.

Key Points

To evaluate the efficacy of therapeutic plasma exchange in managing transfusion-dependent pure red cell aplasia following ABO-incompatible hematopoietic stem cell transplantation.
Examined two patients (N=2) with treatment-refractory, transfusion-dependent pure red cell aplasia following fully HLA-matched, ABO-incompatible hematopoietic stem cell transplantation.
Administered therapeutic plasma exchange regimens consisting of 10 procedures over 3 weeks in Case 1 and 5 procedures over 2 weeks in Case 2.
Both patients achieved transfusion independence, occurring after the seventh therapeutic plasma exchange session in Case 1 and after the first session in Case 2.
Donor-specific red blood cells emerged following therapy, detectable after procedure nine for Case 1 (type A) and procedure five for Case 2 (type B).
Isoagglutinin titers dropped below the level of detection in both individuals, resulting in full erythroid lineage recovery.

Cite This Study

Vivero et al. (2023) studied this question.

synapsesocial.com/papers/6a7e3dae1fdb7ee677c768d5 https://doi.org/10.1002/jca.22041

View Full Paper

Ask AI

Bookmark

Implication

Case series demonstrates resolution of pure red cell aplasia using therapeutic plasma exchange after ABO-incompatible stem cell transplant, highlighting its utility in refractory cases.

Successful treatment of pure red cell aplasia using therapeutic plasma exchange after ABO‐incompatible hematopoietic stem cell transplant

Discussion

Member takes

Implication

Key Points

Cite This Study

Successful treatment of pure red cell aplasia using therapeutic plasma exchange after ABO‐incompatible hematopoietic stem cell transplant

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider